Literature DB >> 21239006

D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging.

Ardeshir R Rastinehad1, Angelo A Baccala, Paul H Chung, Juan M Proano, Jochen Kruecker, Sheng Xu, Julia K Locklin, Baris Turkbey, Joanna Shih, Gennady Bratslavsky, W Marston Linehan, Neil D Glossop, Pingkun Yan, Samuel Kadoury, Peter L Choyke, Bradford J Wood, Peter A Pinto.   

Abstract

PURPOSE: We determined whether there is a correlation between D'Amico risk stratification and the degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging based on targeted biopsies done with our electromagnetically tracked magnetic resonance imaging/ultrasound fusion platform.
MATERIALS AND METHODS: A total of 101 patients underwent 3 Tesla multiparametric magnetic resonance imaging of the prostate, consisting of T2, dynamic contrast enhanced, diffusion weighted and spectroscopy images in cases suspicious for or with a diagnosis of prostate cancer. All prostate magnetic resonance imaging lesions were then identified and graded by the number of positive modalities, including low-2 or fewer, moderate-3 and high-4 showing suspicion on multiparametric magnetic resonance imaging. The biopsy protocol included standard 12-core biopsy, followed by real-time magnetic resonance imaging/ultrasound fusion targeted biopsies of the suspicious magnetic resonance lesions. Cases and lesions were stratified by the D'Amico risk stratification.
RESULTS: In this screening population 90.1% of men had a negative digital rectal examination. Mean±SD age was 62.7±8.3 years and median prostate specific antigen was 5.8 ng/ml. Of the cases 54.5% were positive for cancer on protocol biopsy. Chi-square analysis revealed a statistically significant correlation between magnetic resonance suspicion and D'Amico risk stratification (p<0.0001). Within cluster resampling demonstrated a statistically significant correlation between magnetic resonance suspicion and D'Amico risk stratification for magnetic resonance targeted core biopsies and magnetic resonance lesions (p<0.01)
CONCLUSIONS: Our data support the notion that using multiparametric magnetic resonance prostate imaging one may assess the degree of risk associated with magnetic resonance visible lesions in the prostate.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21239006      PMCID: PMC3169005          DOI: 10.1016/j.juro.2010.10.076

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

1.  MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies.

Authors:  Aristotelis G Anastasiadis; Matthias P Lichy; Udo Nagele; Markus A Kuczyk; Axel S Merseburger; Joerg Hennenlotter; Stefan Corvin; Karl-Dietrich Sievert; Claus D Claussen; Arnulf Stenzl; Heinz-Peter Schlemmer
Journal:  Eur Urol       Date:  2006-03-24       Impact factor: 20.096

2.  Transrectal biopsy of the prostate.

Authors:  C K PEARLMAN
Journal:  J Urol       Date:  1955-09       Impact factor: 7.450

3.  Closed-loop control in fused MR-TRUS image-guided prostate biopsy.

Authors:  Sheng Xu; Jochen Kruecker; Peter Guion; Neil Glossop; Ziv Neeman; Peter Choyke; Anurag K Singh; Bradford J Wood
Journal:  Med Image Comput Comput Assist Interv       Date:  2007

4.  Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications.

Authors:  M S Cookson; N E Fleshner; S M Soloway; W R Fair
Journal:  J Urol       Date:  1997-02       Impact factor: 7.450

5.  Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; B Malkowicz; M Schnall; D Schultz; K Cote; J E Tomaszewski; A Wein
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

6.  Extended sector biopsy for detection of carcinoma of the prostate.

Authors:  P M.A. M D ; T H. Niemann; R R. Bahnson
Journal:  Urol Oncol       Date:  2001-05       Impact factor: 3.498

7.  Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance.

Authors:  Kazutoshi Fujita; Patricia Landis; Brian K McNeil; Christian P Pavlovich
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

8.  Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies.

Authors:  Sheng Xu; Jochen Kruecker; Baris Turkbey; Neil Glossop; Anurag K Singh; Peter Choyke; Peter Pinto; Bradford J Wood
Journal:  Comput Aided Surg       Date:  2008-09

9.  Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

Authors:  Anthony V D'Amico; Judd Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

10.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

View more
  29 in total

1.  Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.

Authors:  Hashim U Ahmed; Oguz Akin; Jonathan A Coleman; Sarah Crane; Mark Emberton; Larry Goldenberg; Hedvig Hricak; Mike W Kattan; John Kurhanewicz; Caroline M Moore; Chris Parker; Thomas J Polascik; Peter Scardino; Nicholas van As; Arnauld Villers
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

2.  Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance.

Authors:  Iqbal Sahibzada; Deepak Batura; Giles Hellawell
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

3.  Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session.

Authors:  Cheng William Hong; Annerleim Walton-Diaz; Soroush Rais-Bahrami; Anthony N Hoang; Barış Türkbey; Lambros Stamatakis; Sheng Xu; Hayet Amalou; M Minhaj Siddiqui; Jeffrey W Nix; Srinivas Vourganti; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

4.  Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer.

Authors:  Marc A Bjurlin; Peter R Carroll; Scott Eggener; Pat F Fulgham; Daniel J Margolis; Peter A Pinto; Andrew B Rosenkrantz; Jonathan N Rubenstein; Daniel B Rukstalis; Samir S Taneja; Baris Turkbey
Journal:  J Urol       Date:  2019-10-23       Impact factor: 7.450

5.  Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.

Authors:  Nabeel A Shakir; Arvin K George; M Minhaj Siddiqui; Jason T Rothwax; Soroush Rais-Bahrami; Lambros Stamatakis; Daniel Su; Chinonyerem Okoro; Dima Raskolnikov; Annerleim Walton-Diaz; Richard Simon; Baris Turkbey; Peter L Choyke; Maria J Merino; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2014-08-09       Impact factor: 7.450

Review 6.  Multiparametric MRI and prostate cancer diagnosis and risk stratification.

Authors:  Baris Turkbey; Peter L Choyke
Journal:  Curr Opin Urol       Date:  2012-07       Impact factor: 2.309

Review 7.  Prostate biopsy for the interventional radiologist.

Authors:  Cheng William Hong; Hayet Amalou; Sheng Xu; Baris Turkbey; Pingkun Yan; Jochen Kruecker; Peter A Pinto; Peter L Choyke; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2014-02-26       Impact factor: 3.464

8.  Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up.

Authors:  Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

9.  Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device.

Authors:  Geoffrey A Sonn; Shyam Natarajan; Daniel J A Margolis; Malu MacAiran; Patricia Lieu; Jiaoti Huang; Frederick J Dorey; Leonard S Marks
Journal:  J Urol       Date:  2012-11-14       Impact factor: 7.450

10.  Prostate diffusion imaging with distortion correction.

Authors:  Rebecca A Rakow-Penner; Nathan S White; Daniel J A Margolis; John Kellogg Parsons; Natalie Schenker-Ahmed; Joshua M Kuperman; Hauke Bartsch; Hyung W Choi; William G Bradley; Ahmed Shabaik; Jiaoti Huang; Michael A Liss; Leonard Marks; Christopher J Kane; Robert E Reiter; Steven S Raman; David S Karow; Anders M Dale
Journal:  Magn Reson Imaging       Date:  2015-07-26       Impact factor: 2.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.